UNLABELLED: Affibody molecules are a class of scaffold proteins being developed into a generalizable approach to targeting tumors. Many 3-helix-based Affibody proteins have shown excellent in vivo properties for tumor imaging and therapy. By truncating one alpha-helix that is not responsible for receptor recognition in the Affibody and maturating the protein affinity through synthetic strategies, we have successfully identified in our previous research several small 2-helix proteins with excellent binding affinities to human epidermal growth factor receptor type 2 (HER2). With preferential properties such as faster blood clearance and tumor accumulation, lower immunogenic potential, and facile and economically viable synthetic schemes, we hypothesized that these 2-helix protein binders could become excellent molecular imaging probes for monitoring HER2 expression and modulation. METHODS: In this study, a 2-helix small protein, MUT-DS, was chemically modified with a metal chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). DOTA-MUT-DS was then site-specifically radiolabeled with an important PET radionuclide, (68)Ga. The resulting radiolabeled anti-HER2 2-helix molecule was further evaluated as a potential molecular probe for small-animal PET HER2 imaging in a SKOV3 tumor mouse model. RESULTS: The 2-helix DOTA-MUT-DS showed high HER2-binding affinity (dissociation constant, 4.76 nM). The radiolabeled probe displayed high stability in mouse serum and specificity toward HER2 in cell cultures. Biodistribution and small-animal PET studies further showed that (68)Ga-DOTA-MUT-DS had rapid and high SKOV3 tumor accumulation and quick clearance from normal organs. The specificity of (68)Ga-DOTA-MUT-DS for SKOV3 tumors was confirmed by monitoring modulation of HER2 protein on treatment of tumor mice with heat shock protein 90 inhibitor 17-N,N-dimethyl ethylene diamine-geldanamycin in vivo. CONCLUSION: This proof-of-concept research clearly demonstrated that synthetic 2-helix (68)Ga-DOTA-MUT-DS is a promising PET probe for imaging HER2 expression in vivo. The Affibody-derived small 2-helix protein scaffold has great potential for developing targeting agents for a variety of tumor-associated biomarkers.
UNLABELLED: Affibody molecules are a class of scaffold proteins being developed into a generalizable approach to targeting tumors. Many 3-helix-based Affibody proteins have shown excellent in vivo properties for tumor imaging and therapy. By truncating one alpha-helix that is not responsible for receptor recognition in the Affibody and maturating the protein affinity through synthetic strategies, we have successfully identified in our previous research several small 2-helix proteins with excellent binding affinities to humanepidermal growth factor receptor type 2 (HER2). With preferential properties such as faster blood clearance and tumor accumulation, lower immunogenic potential, and facile and economically viable synthetic schemes, we hypothesized that these 2-helix protein binders could become excellent molecular imaging probes for monitoring HER2 expression and modulation. METHODS: In this study, a 2-helix small protein, MUT-DS, was chemically modified with a metal chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). DOTA-MUT-DS was then site-specifically radiolabeled with an important PETradionuclide, (68)Ga. The resulting radiolabeled anti-HER2 2-helix molecule was further evaluated as a potential molecular probe for small-animal PETHER2 imaging in a SKOV3 tumormouse model. RESULTS: The 2-helix DOTA-MUT-DS showed high HER2-binding affinity (dissociation constant, 4.76 nM). The radiolabeled probe displayed high stability in mouse serum and specificity toward HER2 in cell cultures. Biodistribution and small-animal PET studies further showed that (68)Ga-DOTA-MUT-DS had rapid and high SKOV3 tumor accumulation and quick clearance from normal organs. The specificity of (68)Ga-DOTA-MUT-DS for SKOV3 tumors was confirmed by monitoring modulation of HER2 protein on treatment of tumormice with heat shock protein 90 inhibitor 17-N,N-dimethyl ethylene diamine-geldanamycin in vivo. CONCLUSION: This proof-of-concept research clearly demonstrated that synthetic 2-helix (68)Ga-DOTA-MUT-DS is a promising PET probe for imaging HER2 expression in vivo. The Affibody-derived small 2-helix protein scaffold has great potential for developing targeting agents for a variety of tumor-associated biomarkers.
Authors: Martin Gotthardt; Julliëtte van Eerd-Vismale; Wim J G Oyen; Marion de Jong; Hanwen Zhang; Edgar Rolleman; Helmut R Maecke; Martin Béhé; Otto Boerman Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Konstantin P Zhernosekov; Dimitry V Filosofov; Richard P Baum; Peter Aschoff; Heiner Bihl; Anatoli A Razbash; Markus Jahn; Mark Jennewein; Frank Rösch Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Vladimir Tolmachev; Anna Orlova; Rikard Pehrson; Joakim Galli; Barbro Baastrup; Karl Andersson; Mattias Sandström; Daniel Rosik; Jörgen Carlsson; Hans Lundqvist; Anders Wennborg; Fredrik Y Nilsson Journal: Cancer Res Date: 2007-03-15 Impact factor: 12.701
Authors: Gang Ren; Jack M Webster; Zhe Liu; Rong Zhang; Zheng Miao; Hongguang Liu; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng Journal: Amino Acids Date: 2011-10-08 Impact factor: 3.520
Authors: Zheng Miao; Gang Ren; Lei Jiang; Hongguang Liu; Jack M Webster; Rong Zhang; Mohammad Namavari; Sanjiv S Gambhir; Faisal Syud; Zhen Cheng Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-15 Impact factor: 9.236
Authors: Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; H Kim Lyerly; Michael R Zalutsky Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057